title: Inhibitory effects of panduratin A on allergy-related mediator production in rat basophilic leukemia mast cells.
abstract: Immediate-type hypersensitivity is characterized by elevated levels of immunoglobulin E (IgE) and activated mast cell plays a crucial role by releasing granule contents, lipid-derived mediators, cytokines, and chemokines. To evaluate the antiallergic effects of panduratin A isolated from Boesenbergia pandurata Roxb., we determined its effects on calcium (Ca(2+)) influx, degranulation, and inflammatory mediators in calcium ionophore A23187 and phorbol 12-myristate 13-acetate (PMA)-stimulated rat basophilic leukemia (RBL-2H3) cells. Panduratin A (20 μM) inhibited secretion of β-hexosaminidase (46.69 ± 9.6 %), histamine (34.32 ± 2.1 %), and Ca(2+) influx (43.84 %). Panduratin A reduced the production of prostaglandin E(2) (PGE(2), 47.58 ± 3.4 %), leukotriene B(4) (LTB(4), 98.15 ± 1.6 %), and the mRNA expression of cyclooxygenase-2, 5-lipoxygenase, interleukin (IL)-4, IL-13, and tumor necrosis factor-α. Furthermore, panduarin A attenuated phosphorylation of Akt, the mitogen-activated protein kinases (MAPK) extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) expression. These results indicate that panduratin A might be useful as an agent against immediate-type hypersensitivity.
authors.affiliation: Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-749, South Korea.
authors.forename: Yuri
authors.initials: Y
authors.lastname: Choi
authors.forename: Myung Suk
authors.initials: MS
authors.lastname: Kim
authors.forename: Jae-Kwan
authors.initials: JK
authors.lastname: Hwang
mesh_terms: D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000235:genetics; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D015550:Cell Degranulation / Q000187:drug effects / Q000276:immunology; D045744:Cell Line, Tumor; D047188:Chalcones / Q000494:pharmacology*; D051546:Cyclooxygenase 2 / Q000235:genetics; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006632:Histamine / Q000378:metabolism; D006636:Histamine Release / Q000187:drug effects* / Q000276:immunology; D006969:Hypersensitivity, Immediate / Q000188:drug therapy*; D007073:Immunoglobulin E / Q000276:immunology; D018836:Inflammation Mediators; D018793:Interleukin-13 / Q000235:genetics; D015847:Interleukin-4 / Q000235:genetics; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism; D015471:Leukemia, Basophilic, Acute / Q000188:drug therapy*; D007975:Leukotriene B4 / Q000096:biosynthesis; D008407:Mast Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D010766:Phosphorylation; D010936:Plant Extracts / Q000494:pharmacology; D011458:Prostaglandins E / Q000096:biosynthesis; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D015398:Signal Transduction / Q000276:immunology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics; D030521:Zingiberaceae / Q000378:metabolism; D001619:beta-N-Acetylhexosaminidases / Q000187:drug effects* / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
chemical_list: D047188:Chalcones; D018836:Inflammation Mediators; D018793:Interleukin-13; D010936:Plant Extracts; D011458:Prostaglandins E; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D007975:Leukotriene B4; D015847:Interleukin-4; C482884:panduratin A; D007073:Immunoglobulin E; D000001:Calcimycin; D006632:Histamine; D001094:Arachidonate 5-Lipoxygenase; D051546:Cyclooxygenase 2; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D048031:JNK Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D001619:beta-N-Acetylhexosaminidases; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium